SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trialResearch article Published on 2020-10-012022-10-05 Journal: International Journal of Infectious Diseases [Category] SARS, 신약개발, 임상, 치료법, 치료제, [키워드] Aerosolized inhalation anti-SARS-CoV-2 Antiviral antiviral drug Antiviral effect Cell Chinese clearance rate clinical COVID-19 COVID-19 patient COVID-19 patients EC50 Effect enrolled evaluated exhibited group healthy in vitro infected with SARS-CoV-2 inhibited Laboratory Lopinavir/ritonavir median time nine Novaferon number Open-label parallel-group prevented primary endpoint Protein Randomized reduction in registry Result SARS-CoV-2 SARS-CoV-2 clearance SARS-CoV-2 entry secondary endpoint significantly higher the SARS-CoV-2 three groups Treatment Trial viral clearance viral clearance rate viral infection viral replication was determined [DOI] 10.1016/j.ijid.2020.07.053 [Article Type] Research article
Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?Review Article Published on 2020-10-012022-10-28 Journal: Aging and Disease [Category] COVID-19, [키워드] Anti-inflammatory effects Cell cellular therapy China clinical clinical trial COVID-19 COVID-19 patient Efficacy Evidence feature ICTRP information investigated option other disease pharmacological agent Pneumonia public health registry respiratory problems Spread STEM stem cell the disease therapy Treatment trials virus WHO World Health Organization [DOI] 10.14336/AD.2020.0608 PMC 바로가기 [Article Type] Review Article
COVID-19 in patients undergoing chronic kidney replacement therapy and kidney transplant recipients in Scotland: findings and experience from the Scottish renal registryResearch Article Published on 2020-10-012022-10-28 Journal: BMC Nephrology [Category] COVID-19, MERS, SARS, [키워드] affected Analysis appear Audit caused Characteristics coronavirus disease COVID-19 COVID-19 in patient data set Descriptive statistics dialysis effective Epidemiology group Haemodialysis Healthcare system high mortality incidence index Infection infection with SARS-CoV-2 intelligence kidney kidney replacement therapy kidney transplant recipient measure Mortality National Observational cohort study Older outcome Patient patients performed Peritoneal dialysis positive prevalent protection Public receiving registry renal Respiratory Coronavirus Result SARS-CoV-2 Scottish shielding Society survival tested the disease therapy unique worldwide pandemic [DOI] 10.1186/s12882-020-02061-8 PMC 바로가기 [Article Type] Research Article
The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countriesArticle Published on 2020-10-012023-07-11 Journal: Journal of the American Academy of Dermatology [Category] SARS, [키워드] COVID toes COVID-19 Dermatology global health macular erythema morbilliform pernio public health registry retiform purpura SARS-CoV-2 urticarial vesicular. [DOI] 10.1016/j.jaad.2020.06.1016 PMC 바로가기
Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational RegistryObservational Study Published on 2020-09-302022-10-04 Journal: International Journal of Stroke [Category] MERS, 임상, [키워드] 95%CI Admission age All cerebrovascular diseases/stroke baseline Cerebral venous thrombosis cerebrovascular Cerebrovascular disease clinically Clustering Cohort cohort of patient coronavirus disease cortical country COVID-19 critically ill patients diagnosed evaluated event events female hemorrhage hospital hospitalized patient ICH in-hospital mortality in-hospital mortality rate incidence rate independent predictor Intervention intracranial hemorrhage laboratory-confirmed Lymphocyte count lymphocyte counts Male sex mechanism medical services mitigate Mortality mortality rate Older age outcome outcomes Patient patients Platelet predictor Primary outcome registry Result risk SARS-CoV-2 severity stroke thrombosis thrombotic event [DOI] 10.1177/1747493020959216 PMC 바로가기 [Article Type] Observational Study
COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care systemResearch Article Published on 2020-09-302022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] 95% CI age blocker Care Clinical management comorbid condition Connecticut Coronary artery disease COVID COVID-19 COVID-19 infection COVID-19 testing death disease elderly failure Health heart heart failure higher risk hospital Hospitalization hotspot hypertension include increased risk Infection large cohort less manuscript Mortality multiple comorbidity Older outcome Patient patient mortality patients patients died Prevalence proportion registry Respiratory failure Result retrospective Retrospective analysis SARS-CoV-2 Spread Symptomatic patients tested was performed [DOI] 10.1371/journal.pone.0238829 PMC 바로가기 [Article Type] Research Article
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19Clinical Trial Published on 2020-09-212022-10-27 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19, [키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical conducted Cooperative COVID-19 death Disease progression Endpoint enrolled Favipiravir Fever group hospital IMPROVE in viral Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza viral clearance with COVID-19 [DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19Clinical Trial Published on 2020-09-212022-10-27 Journal: Antimicrobial Agents and Chemotherapy [Category] Coronavirus, COVID-19, SARS, [키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical conducted Cooperative COVID-19 death Disease progression Endpoint enrolled Favipiravir Fever group hospital IMPROVE in viral Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza viral clearance with COVID-19 [DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19COVID-19로 입원한 환자를 대상으로 한 초기 Favipiravir 요법 대 후기 Favipiravir 요법의 전향적 무작위 공개 표지 시험Clinical Trial Published on 2020-09-212022-08-08 Journal: Antimicrobial Agents and Chemotherapy [Category] 임상, 진단, 치료제, [키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical clinical trials conducted Cooperative COVID-19 death defervescence Disease progression Eligible patients Endpoint enrolled Exploratory endpoints Favipiravir Fever group hospital Hyperuricemia IMPROVE in viral Influenza Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA polymerase RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza Viral viral clearance Viral load Viral RNA viral RNA-dependent RNA polymerase with COVID-19 [DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial
Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registryResearch Article Published on 2020-09-192024-09-02 Journal: BMC Rheumatology [Category] 대상포진, [키워드] Effectiveness Golimumab infliximab registry rheumatoid arthritis Safety [DOI] 10.1186/s41927-020-00145-4 PMC 바로가기 [Article Type] Research Article